FDA Staff Question Safety of Bayer AG and Johnson & Johnson Drug Xarelto

March 17, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters - Increased bleeding and other potential risks are a concern with Bayer AG (BAYG.DE) and Johnson & Johnson's (JNJ.N) blood-thinning drug Xarelto, U.S. regulatory staff said in documents released on Tuesday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Johnson & Johnson Family of Companies Food and Drug Administration (FDA)